SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001178913-14-000942
Filing Date
2014-03-17
Accepted
2014-03-17 08:08:58
Documents
11
Period of Report
2013-12-31

Document Format Files

Seq Description Document Type Size
1 20-F zk1414565.htm 20-F 3612364
2 EXHIBIT 4.18 exhibit_4-18.htm EX-4.18 164984
3 EXHIBIT 4.34 exhibit_4-34.htm EX-4.34 428271
4 EXHIBIT 4.35 exhibit_4-35.htm EX-4.35 213191
5 EXHIBIT 12.1 exhibit_12-1.htm EX-12.1 19596
6 EXHIBIT 12.2 exhibit_12-2.htm EX-12.2 16958
7 EXHIBIT 13.1 exhibit_13-1.htm EX-13.1 5454
8 EXHIBIT 13.2 exhibit_13-2.htm EX-13.2 5382
9 EXHIBIT 15.5 exhibit_15-5.htm EX-15.5 4587
10 pipp.jpg GRAPHIC 95058
11 pwc.jpg GRAPHIC 3663
  Complete submission text file 0001178913-14-000942.txt   4608131
Mailing Address P.O. BOX 45158 19 HARTUM STREET JERUSALEM L3 91450
Business Address P.O. BOX 45158 19 HARTUM STREET JERUSALEM L3 91450 972-2-548-9100
BioLineRx Ltd. (Filer) CIK: 0001498403 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-35223 | Film No.: 14696170
SIC: 2834 Pharmaceutical Preparations